Healthcare / Pharmaceuticals
Global pharmaceutical company leading the GLP-1 obesity and diabetes drug revolution.
View forensic reportAt $841 billion market cap and 41x trailing earnings, Eli Lilly looks expensive by every traditional metric. But Mounjaro and Zepbound are creating a revenue trajectory that makes 41x look cheap in hindsight.
The shift from injectable to oral delivery could expand the addressable GLP-1 market by 3-4x. Lilly's pharmacy partnerships make it a distribution play, not just a drug launch.
Revenue surged 38% to $65.2B in FY2025 as Mounjaro and Zepbound scaled. With manufacturing constraints easing and retatrutide data approaching, we're raising our revenue estimate to $90-100B by 2028.
Foundayo's FDA approval transforms Eli Lilly from an injectable GLP-1 leader into an oral mass-market platform, with revenue already at $65.2 billion and accelerating.
Revenue jumped 45% to $65.2 billion and FCF recovered from near-zero to $9 billion — but at 40.8x trailing earnings, has the market already priced in the miracle?
Lilly's revenue surged from $28.3 billion to $45.0 billion in two years on the back of Mounjaro and Zepbound. At 67x trailing earnings, the market is pricing perfection — and it might be right.